Spero Therapeutics is developing novel therapies to treat highly resistant bacterial infections. The company is in partnership with Roche to develop its first program targeting gram-negative infections. Spero went public in November 2017 (NASDAQ: SPRO).
| Headquarters | Cambridge, MA |
| Website | www.sperotherapeutics.com |
| @Spero_Tx | |
| Pipeline | Phase 1 |
| Partners | Roche, The National Institute of Allergy and Infectious Diseases (NIAID) |